U.S. Awards Up to $4.9M to Prepare First Ibogaine PTSD Studies
U.S. Health and Human Services Secretary Robert Kennedy Jr. said on Thursday that his department is allocating up to $4.9 million toward groundwork for the first domestic studies of the psychedelic drug ibogaine for post-traumatic stress disorder, according to The Hindu. Kennedy said the funding will not go directly to patient trials, but will cover groundwork needed to manufacture, dose and design studies of the drug, with additional awards potentially exploring addiction treatment, The Hindu reported.
Safety Risks, Legal Status and Beond Data
Derived from a West African shrub, ibogaine can cause intense hallucinations, nausea, vomiting, tremors and sometimes fatal irregular heart rhythms, and remains illegal in the same ultra-restrictive U.S. class as LSD and ecstasy, The Hindu reported. Kennedy said federal officials will receive data and treatment guidance from Texas-based Beond Inc., which has treated over 3,000 patients with ibogaine in Mexico, adding that he believes this will dramatically accelerate the clinical trial and approval process. Veterans Affairs Secretary Doug Collins joined Thursday's announcement, saying the joint effort will prioritise safety and rigorous science for veterans living with PTSD. The FDA's ibogaine safety proposal excludes participants with a baseline corrected QT interval of 430 milliseconds or longer and requires pausing a study if a participant's corrected QT interval remains above 500 milliseconds for more than two days, according to Detox.com. Texas awarded $50 million for ibogaine trials led by UTHealth Houston and UTMB Health, and Arizona committed $5 million to a brain injury trial at Barrow Neurological Institute, according to Detox.com.
Background on Federal Psychedelics Review
Currently, most available data comes from patients who paid $10,000 to $20,000 for treatment courses at clinics in Mexico or other countries, often with cardiac monitoring and emergency workers on standby, The Hindu reported. Thursday's funding follows an April executive order by President Donald Trump directing federal agencies to speed up psychedelics research after podcaster Joe Rogan texted him about ibogaine, while three Food and Drug Administration applications involving psilocybin and MDMA await decisions within weeks or months, The Hindu said.
Background
ARPA-H selected research teams led by Mark Cuban Cost Plus Drug Company, PBC and Beond, Inc. under an initial commitment of up to $4.9 million over five years, according to U.S. Department of Health and Human Services.
HHS aims to make any FDA-approved ibogaine medicine available at the cost of production plus a fair margin, according to U.S. Department of Health and Human Services.
The National Institute of Mental Health published a $20 million Notice of Funding Opportunity for a rapid-acting psychotropic research network, with award recipients to be announced in summer 2027, according to U.S. Department of Health and Human Services.
The FDA proposal recommends inpatient units with continuous heart rhythm monitoring for up to 36 hours after dosing and starting doses capped at 10 milligrams per kilogram of body weight, according to Detox.com.